Found 4 matches for
It is difficult to test whether painkillers work for very young children and we often don't know the best dose to give. But if Professor Rebeccah Slater and her research team at Oxford are successful we may find alternative ways to measure pain in babies and may eventually be able to offer babies some better options to soothe their pain.
Neuromuscular Diseases Research
6 May 2021
Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.
Awards & Appointments Neuromuscular Diseases
9 December 2020
PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.
Awards & Appointments Neuromuscular Diseases Public Engagement
25 August 2020
The awardees for the second round of the University of Oxford’s Enriching Engagement funding scheme have now been announced, including a project from Paediatrics.
Neuromuscular Diseases Publication
12 August 2020
Oligonucleotides - short DNA or RNA molecules - have great therapeutic application for a range of diseases. Yet, their potential has not been fully unleashed because of challenges linked to efficient delivery. Read more to find out about recent developments in oligonucleotide modifications, and the platforms that may be used to deliver them to target sites.